Pregnancy after solid organ transplantation: a guide for obstetric management.

Reviews in obstetrics & gynecology Pub Date : 2013-01-01
Neha A Deshpande, Lisa A Coscia, Veronica Gomez-Lobo, Michael J Moritz, Vincent T Armenti
{"title":"Pregnancy after solid organ transplantation: a guide for obstetric management.","authors":"Neha A Deshpande, Lisa A Coscia, Veronica Gomez-Lobo, Michael J Moritz, Vincent T Armenti","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Successful pregnancy outcomes are possible among all solid organ transplant recipients. Patients should be fully counseled regarding the potential adverse fetal outcomes, including prematurity and low birth weight. Transplant recipients are at an increased risk for both maternal and neonatal complications and should be seen by a high-risk obstetrician in conjunction with their transplant teams. Ideally, preconception counseling begins during the pretransplantation evaluation process. Initiating contraception early after transplantation is ideal, and long-acting reversible methods such as intrauterine devices and subdermal implants may be preferred. Pregnancy should be avoided for at least 1 year after transplantation to limit the potential risks of early pregnancy that may adversely affect both allograft function and fetal well-being. Hypertension, diabetes, and infection should be monitored and treated to minimize fetal risks during pregnancy. Maintenance of current immunosuppression is usually recommended, with the exception of mycophenolic acid products, which (when possible) should be discontinued before conception and replaced with an alternative medication. Throughout pregnancy, immunosuppression must be maintained at appropriate dosing to avoid graft rejection. During labor and delivery, cesarean delivery should be performed for obstetric reasons only. A multidisciplinary team should manage pregnant transplant recipients before, during, and following pregnancy. Breastfeeding and long-term in utero exposure to immunosuppressants for offspring of transplant recipients continue to require further investigation but have been encouraged by recent reports. Continued reporting of post-transplantation pregnancy outcomes to the National Transplantation Pregnancy Registry is highly encouraged. </p>","PeriodicalId":21170,"journal":{"name":"Reviews in obstetrics & gynecology","volume":"6 3-4","pages":"116-25"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002187/pdf/RIOG006003_0116.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in obstetrics & gynecology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Successful pregnancy outcomes are possible among all solid organ transplant recipients. Patients should be fully counseled regarding the potential adverse fetal outcomes, including prematurity and low birth weight. Transplant recipients are at an increased risk for both maternal and neonatal complications and should be seen by a high-risk obstetrician in conjunction with their transplant teams. Ideally, preconception counseling begins during the pretransplantation evaluation process. Initiating contraception early after transplantation is ideal, and long-acting reversible methods such as intrauterine devices and subdermal implants may be preferred. Pregnancy should be avoided for at least 1 year after transplantation to limit the potential risks of early pregnancy that may adversely affect both allograft function and fetal well-being. Hypertension, diabetes, and infection should be monitored and treated to minimize fetal risks during pregnancy. Maintenance of current immunosuppression is usually recommended, with the exception of mycophenolic acid products, which (when possible) should be discontinued before conception and replaced with an alternative medication. Throughout pregnancy, immunosuppression must be maintained at appropriate dosing to avoid graft rejection. During labor and delivery, cesarean delivery should be performed for obstetric reasons only. A multidisciplinary team should manage pregnant transplant recipients before, during, and following pregnancy. Breastfeeding and long-term in utero exposure to immunosuppressants for offspring of transplant recipients continue to require further investigation but have been encouraged by recent reports. Continued reporting of post-transplantation pregnancy outcomes to the National Transplantation Pregnancy Registry is highly encouraged.

实体器官移植后妊娠:产科管理指南。
所有接受实体器官移植的患者都有可能成功怀孕。患者应充分了解胎儿可能出现的不良后果,包括早产和出生体重不足。移植受者罹患孕产妇和新生儿并发症的风险都会增加,因此应由高风险产科医生与其移植团队共同接诊。理想情况下,孕前咨询应在移植前评估过程中开始。移植后尽早开始避孕是理想的选择,长效可逆避孕法(如宫内节育器和皮下植入)可能是首选。移植后至少一年内应避免妊娠,以限制可能对异体移植功能和胎儿健康产生不利影响的早孕潜在风险。应监测并治疗高血压、糖尿病和感染,以尽量减少妊娠期对胎儿的风险。通常建议维持目前的免疫抑制,但霉酚酸类药物除外,在可能的情况下,应在受孕前停用该类药物,并用其他药物替代。在整个妊娠期间,必须维持适当剂量的免疫抑制,以避免移植物排斥反应。在分娩过程中,应仅出于产科原因进行剖宫产。在妊娠前、妊娠期间和妊娠后,应由一个多学科团队对妊娠移植受者进行管理。移植受者后代的母乳喂养和子宫内长期暴露于免疫抑制剂的问题仍需进一步研究,但最近的报告鼓励了这一点。我们鼓励继续向国家移植妊娠登记处报告移植后的妊娠结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信